Sorafenib对前列腺癌DU145细胞的抑制作用的研究  

Inhibitory action of Sorafenib on the androgen independent prostate cancer cell line DU145 in vitro

作　　者：高锐[1] 毛厚平[1] 周辉良[1] 吕夷松[1] 江涛[1] 许宁[1] 

机构地区：[1]福建医科大学附属第一医院泌尿外科,福州350005

出　　处：《现代泌尿生殖肿瘤杂志》2010年第6期347-349,共3页Journal of Contemporary Urologic and Reproductive Oncology

摘　　要：目的观察索拉非尼(Sorafenib)对雄激素非依赖性前列腺癌DU145细胞的抑制作用。方法用不同浓度Sorafenib处理前列腺癌DU145细胞24、48和72h后,MTT法检测Sor-afenib对DU145细胞的抑制作用,流式细胞仪检测细胞凋亡变化,Western blot检测不同浓度Sor-afenib处理72h后DU145细胞内ERK和Bcl-2的表达。结果 Sorafenib能显著抑制DU145细胞的体外生长,呈时间与剂量依赖性。DU145细胞凋亡率随着Sorafenib剂量的增加而增大,具有良好的量效关系(P<0.01);Sorafenib处理DU145细胞72h后,ERK和Bcl-2蛋白的表达明显下调(P<0.01)。结论 Sorafenib抑制DU145细胞增殖、诱导细胞凋亡,可显著抑制雄激素非依赖性前列腺癌细胞的体外生长。Objective To study the inhibitory effects and mechanism of Sorafenib on andro- gen-independent prostate cancer cell line DU145. Methods After being treated with 1-25 μmol Sorafenib for 24-72 h, the inhibiting effece of Sorafenib on the proliferation of DU145 cells was observed by MTT assay, their apoptosis was inspected by flow cytometery （FCM）. The levels of ERK and Bcl-2 in DU145 cells were tested by Western blot. Results Sorafenib could effectively inhibit the growth of androgen independent prost0te cancer cell line DU145 cells in time-dependent and dosedependent manners, induced apoptosis as well （P^0.01）. Sorafenib could decrease the levels of ERK and Bcl-2 in cell line DU145 in a dose-dependent manner （P〈0.01）. Conelasions Sorafenib could significantly inhibit the growth of androgen independent prostate cancer cells DU145 in vitro.

关 键 词：SORAFENIB 前列腺肿瘤 

分 类 号：R737.25[医药卫生—肿瘤]